Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predict relapse of CML patients receiving allogeneic SCT. Minimal residual disease was analyzed by real-time quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR) at day 100 (d100) in 38 patients with 41 year follow-up after conventional non-T-cell-depleted SCT. Normal ABL control values from 1724 follow-up blood samples were used to define an RQ-PCR amplifiability index and the limits of reliable use of BCR-ABL ratios. We then compared the 14 patients with a highlevel d100 BCR-ABL/ABL ratio (X10
Introduction
Until recently, allogeneic stem cell transplantation (SCT) was considered to be the only curative treatment for patients with chronic myeloid leukemia (CML). [1] [2] [3] However, relapse, observed in 20-60% of patients, remains a major adverse outcome after SCT. [4] [5] [6] Early recognition of relapse at the molecular level may provide a window for therapeutic intervention when residual disease remains at low levels. Several studies have investigated whether there was a correlation between relapse risk and molecular BCR-ABL detection after SCT. [7] [8] [9] [10] [11] [12] [13] Most used qualitative polymerase chain reaction (PCR), leading to conflicting results. [7] [8] [9] [10] [11] [12] [13] It has, however, been suggested that a single positive qualitative PCR for BCR-ABL after SCT was associated with an increased risk of relapse. 14 More recently, Olavarria et al. have suggested that early (3-5 months) detection of BCR-ABL transcripts by real-time quantitative reverse transcriptasepolymerase chain reaction (RQ-PCR) was associated with an increased risk of relapse in CML patients following standard allogeneic SCT, whereas Lange et al. 16 have shown that slow reduction of RQ-PCR for BCR-ABL after allogeneic SCT with non-myeloablative conditioning was also associated with a higher relapse risk. Although evaluation of BCR-ABL kinetics is useful in individual patient management, a uniform cutoff is necessary for therapeutic stratification within prospective studies. This requires the identification of a reproducible method for the expression of BCR-ABL levels, particularly within multicenter trials.
Real-time quantitative reverse transcriptase-polymerase chain reaction is a rapid and sensitive method for quantification of target genes, including at minimal residual disease (MRD) levels, but consensus regarding optimal expression of normalized results has not yet been fully achieved. Raw data need to be normalized for RNA/cDNA quantity and quality and for the efficiency of reverse transcription (RT) (the 'amplifiability') by quantitation of an internal housekeeping gene control from the same cDNA. [17] [18] [19] Results then need to be expressed relative to a calibrator. Real-time quantitative reverse transcriptase-polymerase chain reaction can only be considered to be quantitative when the MRD level is within the reproducible range of the standard curve and when cDNA 'amplifiability', reflected by the cycle threshold (C t ) value of the control gene, is within acceptable limits, as excessive correction leads to erroneous results, particularly at levels of MRD below 10 À2 . Consensus regarding the limits of correction for a given housekeeping gene is also desirable. The use of different control genes and/or different forms of data expression makes it difficult to compare data between studies. The European against Cancer (EAC) framework, after testing 14 potential control genes, concluded that the ABL gene represented an appropriate choice. 20 ABL levels do, however, vary between different cell types, including in leukemic blasts and cell lines and between laboratories, when this depends mainly on variable retrotranscription efficiency.
In the present study, we have tested the pertinence of ABL normalization on a series of 38 CML patients allografted in chronic or accelerated phase, whose MRD was analyzed by a standardized RQ-PCR technique validated by the EAC network. We show that ABL represents a valid housekeeping gene for normalization in CML and have identified the acceptable limits of such normalization, thus contributing to improved intercenter reproducibility. We demonstrate that BCR-ABL/ABL ratios at one early time point, 100 days after SCT (d100), is a strong independent predictive factor for relapse, thus allowing early therapeutic adjustment in allografted CML patients.
Patients and methods

Patient population
Between 1992 and 2002, 38 CML patients allografted in two Paris hospitals were selected for study according to the following criteria: CML allografted in chronic or accelerated phase; minimum of 12 months survival after SCT and RNA available around d100 (range 82-118 days) after SCT.
Clinical characteristics for these patients are summarized in Table 1 . Median ages at diagnosis and at transplant were, respectively, 35.9 years (17-57) and 37 years 
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V Asnafi et al either frozen using standard techniques for later RNA extraction or used directly to prepare RNA as described previously. 21 ComplementaryDNA was prepared using EAC criteria from 1 mg RNA as described. 20, 22 C t values of samples were determined using a fixed fluorescence threshold of 0.1 for a 7700 real-time PCR machine (AppliedBiosystems, Foster City, CA, USA).
Molecular monitoring
All samples (BM or PBL) were analyzed in duplicate by RQ-PCR on an ABI 7700 (AppliedBiosystems, Foster City, CA, USA) using the EAC M-BCR-ABL set. 22 Divergent data were confirmed by a novel duplicate assay. Two non-template control and two nonamplifiable control were added to each assay. The threshold was fixed at 0.2.
Data expression
Two simultaneous BCR-ABL quantification methods were evaluated, either relative to a K562 cell line dilution series or a BCR-ABL/ABL ratio. K562 dilution series were established from 10 À1 to 10 À6 serial dilutions of BCR-ABL b3-a2-positive K562 cell line RNA from into a BCR-ABL-negative cell line RNA (U937). The 10 À5 dilution of K562 corresponds to approximately 10 copies of BCR-ABL plasmid (data not shown). Reproducible sensitivity was at the 10 À5 K562 dilution point (10 copies of BCR-ABL plasmid). BCR-ABL to ABL ratios were calculated using the difference of C t values of ABL and BCR-ABL using a threshold of 0.1 by the following formula:
ABL PCR yields were evaluated by the slope of the dilution series and demonstrated the same range of efficiency, of approximately 100% (data not shown). Consequently, the formula can be simplified to:
Relapse definition
Molecular relapse was defined by increasing BCR-ABL/ABL ratios at three consecutive evaluations over a period of at least 2 months or BCR-ABL/ABL ratios above 10 À3 at two consecutive evaluations.
Statistical analysis
ABL expression comparisons were performed using a MannWhitney non-parametric test. The Student t-test, the w 2 test or the Fisher exact test were employed to compare the distribution of clinical characteristics between groups when appropriate. Overall survival (OS) and disease-free survival (DFS) were calculated according to Kaplan-Meier method. 23 Survival curves were compared by the log-rank test. 24 In multivariate analysis, a Cox proportional hazards model 25 was used to identify patients' characteristics that have independent effects on the probability of relapse and to quantify their size effects. Survival curves were analyzed using Prism software (GraphPad Software Inc., San Diego, CA). Statistical analyses were performed with S-PLUS 6.0 Software Professional Release 2 (Insightful Corp., Nanterre, FR).
Results
ABL expression in CML samples
The use of ABL for BCR-ABL normalization is potentially limited by its inclusion in the fusion transcript. We decided to evaluate the usefulness of ABL quantification using the EAC set in CML. 20 We first analyzed the distribution of ABL C t values in 1794 follow-up (1263 CML) PB samples ( Figure 1a , class interval of 0.4 C t ). The ABL C t distribution peak was centered at 25.8 and corresponded to a normal distribution with a standard deviation of 1.8. We therefore used a reference ABL C t value of 25.8, which was similar to values reported by the EAC from 15 distinct 20 The 95% reference interval was defined between the 2.5 (24.3, 95% confidence interval (CI) 24.2-24.5) and 97.5 (30.5, 95% CI 29.9-31.6) centiles, to give a normal range of C t 24.3-30.5.
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We then compared PB follow-up values of ABL to different PB diagnostic samples for BCR-ABL-positive and -negative myeloproliferative disorders (MPD), BCR-ABL-positive and -negative B-cell acute lymphoblastic leukemias (ALL), lymphoproliferative disorders (LPD), T-cell ALL, acute myeloid leukemias and nonHodgkin's lymphomas (Figure 1b) . No significant differences were found between follow-up samples (n ¼ 1794) and BCR-ABL-positive MPD diagnosis samples (n ¼ 99; P ¼ 0.627 using a Mann-Whitney assay), showing that ABL is a relevant housekeeping gene at diagnosis and follow-up in CML. In contrast, significantly lower ABL values (Po0.001) were seen between follow-up samples and diagnostic T-and B-lineage acute lymphoblastic leukemias samples, BCR-ABL-positive B-ALL included.
cDNA and RNA quality index amplifiability index
The quality of a follow-up sample, which results from the quality of the cDNA and RNA and the efficiency of retrotranscription and amplification, should be defined in order to reflect the degree of correction and the limits of negativity. We calculated an 'amplifiability' index (AI) using the DC t method and our reference value of ABL: AI ¼ 2 ð25:8ÀCt ABL sampleÞ . For instance, the AI of a sample with an ABL C t of 29.1 would be 0.1 meaning that the amplifiability of the cDNA is one-tenth that of an optimal cDNA. All d100 samples were AI superior to 0.1 (C t range 23.9-29).
Comparison of calibration relative to K562 and BCR-ABL/ABL ratios Although a wide variety of methods of expression of BCR-ABL results have been used, there is increasing consensus for the use of BCR-ABL to ABL ratios. We compared results expressed relative to K562 cell line dilutions to a ratio of expression between BCR-ABL and ABL on 80 PB diagnostic samples and 891 PB MRD-positive follow-up samples with an ABL C t lower than 30.5 ( Figure 2 ). The Pearson correlation coefficients were 0.980 and 0.979, respectively, demonstrating the very high redundancy of these two methods, albeit in a single center setting. We decided to use BCR-ABL/ABL ratios as they can be calculated either from plasmid calibration or from DC t , and are in keeping with current trends in international standardization.
BCR-ABL was considered to be quantifiable if the MRD assay was above the threshold of technical sensitivity (10 À5 of K562 or 10 plasmid copies) and if AI values were higher than 0.04 (i.e. 1 25 th, ABL C t o30.5 in our laboratory). Below this threshold, samples with detectable BCR-ABL transcripts were considered to be positive but not quantifiable, whereas those without detectable BCR-ABL transcripts were considered as un-interpretable and were excluded.
BCR-ABL RQ-PCR on d100 post-SCT
At d100 after allogeneic SCT, BCR-ABL was detectable by RQ-PCR in 19 of the 38 (50%) patients. Of the 19 d100 BCR-ABL-positive patients, five were below the threshold of 10 À4 of BCR-ABL/ABL ratios, whereas 14 were above this threshold. Positivity above 10
À4 was found at the same frequency in BM (6/ 18) and blood (8/20 
Comparison of clinical and biological features between high and low/negative MRD groups
As shown in Table 1 , the two groups were comparable in terms of sex distribution, age at diagnosis and at SCT and disease status at transplantation. Although the median interval from diagnosis to SCT was longer in the high MRD group, the difference was not statistically significant (median7s.d.: 29738 compared to 16710 months, P ¼ 0.216). There were no differences in conditioning regimen, type of graft or occurrence of acute and chronic GVHD between the two groups ( Table 1) . d100 BCR-ABL/ABL ratio is an independent predictive factor of relapse risk and disease-free survival but not overall survival after allogeneic stem cell transplantation At a median follow-up of 76.9 months after SCT (range 44.5-128.9 months), 18 of the 38 patients had undergone molecular relapse. The incidence of relapse was significantly higher in the high MRD group (11/14 (79%)) compared to that of the low/ negative MRD group (7/24 (29%)) (P ¼ 0.009) ( Table 1 and Figure 3a) . Relapse was seen in 5/6 patients with MRD high d100 results in BM, which was not different from the 6/8 relapse rate in patients with MRD high positivity in PB. Median time from SCT to relapse was shorter in the high MRD group, but the difference was not statistically significant (Table 1 , P ¼ 0.27). As shown in Figure 3b , the increased incidence of relapse in the high MRD level group was associated with a significantly shorter DFS compared to that of patients with low/negative MRD levels at d100 after SCT (P ¼ 0.0006).
Clinical features potentially associated with relapse were then analyzed in univariate and multivariate models ( Table 2 ). The BCR-ABL/ABL ratio at d100 was the only significant predictive factor of relapse in both univariate and multivariate analysis. The relative risk of relapse in the high MRD group compared to the low/negative MRD group was of 4.2 (95% CI, 2.2-18.1, 
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V Asnafi et al (P ¼ 0.0006)) in univariate analysis and of 8.9 (95% CI, 2.5-31.6, P ¼ 0.0007) in multivariate analysis. After a median follow-up of 76.9 months post-SCT, five of the 38 patients (13%) had died, two (9%) in the low/negative MRD group and three (20%) in the high MDR group (not significant). It is noteworthy that the two patients who died in the low/negative MRD group did so from chronic GVHD with no evidence of relapse, whereas the three deaths in the high MRD group had relapsed.
Univariate analysis of clinical features potentially associated with overall survival (identical to those analyzed for relapse) revealed that the d100 MRD level was not a factor influencing overall survival (Table 3 ). Significant predictive factors of OS in this study were the occurrence of acute GVHD of grade X2 and the occurrence of chronic GVHD, in particular of extensive chronic GVHD (Table 3) .
Discussion
Treatment of CML has considerably changed as the development of specific anti-BCR-ABL tyrosine kinase inhibitors such as imatinib mesylate (Gleevec s ). [26] [27] [28] [29] Despite this, allogeneic SCT remains the only proven curative treatment for CML [1] [2] [3] and might be the only efficient alternative for patients who develop resistance to anti-tyrosine kinase therapy. 30, 31 Relapse is, however, frequent after allogeneic SCT (20-60%). [4] [5] [6] Early detection of molecular relapse before clinical relapse might improve the outcome of these patients by allowing better control of the disease by the use of immunotherapy such as low doses of BCR-ABL RQ-PCR d100 post-SCT V Asnafi et al donor lymphocyte infusion (DLI) or, in chemosensitive patients, by the use of tyrosine kinase inhibitors. Correlation of BCR-ABL transcript levels with the risk of relapse give conflicting results. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] To our knowledge, the only two published quantitative studies showed that detectable BCR-ABL within the first 3-5 months following allogeneic SCT was associated with a higher relapse rate. 15, 18 None allowed the distinction of clear patient subgroups based on a BCR-ABL RQ-PCR level at one precise time point post-SCT. Our study confirms the results of the aforementioned quantitative series, but also shows that the result of d100 BCR-ABL RQ-PCR is the only significant factor predictive of relapse in both univariate and multivariate analyses when compared to classical predictive factors of relapse such as time from diagnosis to transplant, disease status at transplant and use of a T-cell-depleted graft. [32] [33] [34] The absence of predictive value of these factors in our study is probably explained by the low number of patients, thus emphasizing the predictive power of d100 BCR-ABL MRD. We therefore suggest that d100 BCR-ABL RQ-PCR values above 10 À4 should lead to closer molecular monitoring and early treatment of relapse by either low doses of DLI or tyrosine kinase inhibitors. Alternatively, d100 values could be used to randomize patients to 'prophylactic' DLI or use of DLI on confirmed molecular relapse, as defined above. It is to be noted that these data were generated from ficolled mononuclear cells of both blood and BM origin. The proportion of positive samples and of relapsing patients did not differ with the type of sample. As current recommendations are increasingly based on analysis of red cell-depleted un-ficolled samples, it will be important to determine whether such d100 samples have comparable prognostic significance.
Therapeutic stratification in multicenter studies based on a single time point implies reproducible uniform expression of results. There is increasing consensus for expression of BCR-ABL results as a BCR-ABL ratio, rather than relative to a cell line or plasmid standard curve. This avoids the limitations of expressing results relative to cell lines, which can vary between laboratories and which are not available for many RQ-PCR targets. The use of plasmid copy numbers for expression of individual patient values is unsatisfactory, as copy numbers vary between laboratories for a given target unless fully standardized, complicating interpretation of results. They also represent a contamination risk and their amplifiability reflects only the PCR step and not the efficacy of retrotranscription, when most RQ-PCR variability arises. Although we have demonstrated a very tight correlation between quantification relative to the K562 cell line and BCR-ABL ratios, it should be emphasized that this is in a single centre setting, and it is likely that BCR-ABL ratios will be easier to standardize in a multicenter setting than expression relative to either cell lines or plasmids. The reliability of BCR-ABL/ABL ratios is, however, dependent on the RNA quality, as excessive correction can lead to decreased reproducibility, particularly for low-level positivity around the 10 À4 levels that are increasingly used for therapeutic stratification. It is also important that prescribing clinicians are aware of this. We therefore propose a simple application of ABL values (the amplifiablity index or AI) as a method of expressing sample quality/amplifiability to prescribing clinicians, of identifying reasonable limits for correcting target quantification and for assessing inter-laboratory variability in Q-PCR and retrotranscription efficiency. The AI can easily be calculated within each diagnostic laboratory from the normal distribution of ABL values either for all samples or, after exclusion of diagnostic samples in order to avoid cases with low C t ABL values, as demonstrated here. These are essentially restricted to ALL, when they are significantly lower than both diverse follow-up and diagnostic CML values. We have set the limits for an acceptable AI at 0.04 ( 1 25 th of the median ABL value or C t o30.5 in our laboratory). It will be interesting to evaluate variability in AI range, both within laboratories using EAC standardized protocols, and those using different ABL amplification primers and RQ-PCR techniques.
Interestingly, although not statistically significant because of low numbers, only six of the 11 patients who relapsed in the high MRD group benefited from DLI compared to all seven of the relapsed patients in the low/negative MRD group. This was owing to more contraindications to DLI because of severe GVHD in the high MRD group. This observation reinforces the relevance of d100 MRD quantification in CML after allograft not only for the identification of patients at a higher risk of relapse but potentially also for those with a higher risk of resistance to immunotherapeutic intervention because of resistance and/or escape from CTL cytotoxicity.
Despite its high correlation with relapse, d100 MRD was not predictive of survival in this study. The high sensitivity of CML cells to immunointervention with DLI and/or to tyrosine kinase inhibitors probably explains the low mortality observed in our series; 2/24 (8.3%) and 3/14 (21.4%) in the low and high MRD groups, respectively, NS. All relapsing patients treated with either DLI and/or imatinib mesylate achieved complete remission. It is, however, noteworthy that the two patients who died in the low MRD group did so from GVHD incomplete remission, whereas the three patients who died in the high MRD group did so from evolving disease.
In conclusion, single-point BCR-ABL/ABL d100 ratios allowed identification of distinct CML patient subgroups following allograft, with local ABL normal ranges defining the limits of reliable use of these ratios. The potential applicability of these results in a multicenter setting should be tested in a prospective manner.
